Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid tumours and ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals, though skepticism remains.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

The San Francisco 49ers had a dreadful season, but there were still some silver linings. Injuries decimated the 49ers' offense throughout the year, helping sink them from Super Bowl participants ...

In a significant industry move, Eli Lilly announced plans to acquire Scorpion Therapeutics' experimental cancer therapy, STX-478, for $2.5 billion. This acquisition aims to bolster Eli Lilly's cancer ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...